Marksans closes FY26 with record ₹3,033 cr revenue as Q4 UK sales hit all-time high
Full-year profit rose 9.8% to ₹420 crore. The fourth quarter accelerated, with UK sales at a record and Australia/New Zealand revenue doubling sequentially.
— 4 earlier stories on Marksans Pharma Ltd. →What's new
- Q4 revenue grew 23.1% to ₹891 crore; PAT jumped 64.3%.
- UK posted its highest-ever quarterly revenue; Australia and NZ sales doubled sequentially.
- Launched 112 new US SKUs; expanded into Germany, Canada, and Ireland.
Why this matters
The Q4 acceleration shows the UK recovery is gaining force. With the major capex cycle winding down and ₹990 crore in cash, the business is shifting from investment to returns.
What we're watching
- Whether the UK recovery sustains its new quarterly run-rate.
- Revenue traction from the new geographic expansions.
- Post-capex cash deployment strategy.
The full read
Marksans Pharma delivered a record FY26, with revenue touching ₹3,033 crore and net profit of ₹420 crore. The real story is in the fourth quarter, where revenue jumped 23.1% to ₹891 crore and profit after tax surged 64.3%. The catalyst was a sharp recovery in the UK, which posted its best-ever quarter, and a sequential doubling in Australia and New Zealand. The company is also broadening its base, launching 112 new SKUs in the US and entering Germany, Canada, and Ireland. With ₹990 crore in cash and its major spending cycle winding down, the next phase is less about building capacity and more about generating returns from the assets now in place. The results were anticipated by the market.
Questions answered
- What drove the acceleration in the fourth quarter?
- Q4 revenue grew 23.1% to ₹891 crore, powered by the UK market achieving its highest-ever quarterly sales and a doubling in Australia and New Zealand revenue sequentially.
- How did the full-year results compare to prior expectations?
- Full-year revenue of ₹3,033 crore met the company's prior guidance. Net profit for the year was ₹420 crore, up 9.8%.
- What is the significance of the cash balance and capex comment?
- The company ended the year with ₹990 crore in cash. Management stated the major capex cycle is nearing completion, pointing to lower future capital spending.
- What new markets did the company enter?
- Beyond its core US and UK operations, Marksans expanded into Germany, Canada, and Ireland during the year. It also launched 112 new stock-keeping units in the US.
Story so far
All notes on MARKSANS →- 26 May 2026 · 1:31 PM IST Marksans closes FY26 with record ₹3,033 cr revenue as Q4 UK sales hit all-time high
- today Marksans plans ₹4,000 cr revenue by FY28, but the call transcript adds nothing new
- 7d ago Marksans shelves ₹100 cr plant, sticks to ₹4,000 cr target
- 8d ago Marksans Pharma profit jumps 60% on standalone basis for FY26
- 8d ago Marksans Pharma profit climbs 60% on standalone basis for FY26